<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066909</url>
  </required_header>
  <id_info>
    <org_study_id>B7601002</org_study_id>
    <secondary_id>2014-003776-23</secondary_id>
    <nct_id>NCT02066909</nct_id>
  </id_info>
  <brief_title>A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers</brief_title>
  <official_title>A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Western And Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and plasma concentrations of PF-06649751 in
      healthy volunteers following one or two times daily oral dosing of PF-06649751 for 14 days
      (Cohorts 1 - 4), 21 days (Cohort 5), or 28 days (Cohorts 6 - 8). Cohort 9 will dose Japanese
      healthy volunteers in a manner identical to Cohort 4 and is intended to bridge the
      safety/tolerability and PK data from the Western and Japanese populations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Supine and standing vital sign measurements</measure>
    <time_frame>Days 1 - 18 (Cohorts 1 - 4, 9), Days 1 - 25 (Cohort 5), Days 1 - 32 (Cohorts 6 - 8) and follow-up</time_frame>
    <description>Measurement of blood pressure and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of unchanged drug excreted in urine relative to dose (Ae%)</measure>
    <time_frame>Day 14 (Cohorts 1 - 4, 9), Day 21 (Cohort 5), Day 28 (Cohorts 6 - 8)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLR)</measure>
    <time_frame>Day 14 (Cohort 1 - 4, 9), Day 21 (Cohort 5) and Day 28 (Cohorts 6 - 8)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau)</measure>
    <time_frame>Day 1, Day 14 (Cohorts 1 - 4, 9), Day 1 and Day 21 (Cohort 5), Day 1 and Day 28 (Cohorts 6 - 8)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1, Day 7, Day 14 (Cohorts 1 - 4, 9), Day 1 and 21 (Cohort 5), Day 1 and 28 (Cohorts 6 - 8)</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Day 1, Day 7, Day 14 (Cohorts 1 - 4, 9), Day 1 and 21 (Cohort 5), Day 1 and 28 (Cohorts 6 - 8)</time_frame>
    <description>Time for Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>Days 14 - 18 (Cohorts 1 - 4, 9), Days 21 - 25 (Cohort 5), Days 28 - 32 (Cohorts 6 - 8)</time_frame>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>Days 14 - 18 (Cohorts 1 - 4, 9), Days 21 - 25 (Cohort 5), Days 28 - 32 (Cohorts 6 - 8)</time_frame>
    <description>Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>Days 14 - 18 (Cohorts 1 - 4, 9), Days 21 - 25 (Cohort 5), Days 28 - 32 (Cohorts 6 - 8)</time_frame>
    <description>Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Concentration (Ctrough)</measure>
    <time_frame>Day 1 to 14 (Cohorts 1 - 4, 9), Day 1 to 21 (Cohort 5), Day 1 to 28 (Cohorts 6 - 8)</time_frame>
    <description>Minimum concentration pre-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of accumulation for AUCtau (Rac AUCtau)</measure>
    <time_frame>Day 1 and 14 (Cohorts 1 - 4, 9), Day 1 and 21 (Cohort 5), Day 1 and 28 (Cohorts 6 - 8)</time_frame>
    <description>Ratio of accumulation for AUCtau. Corrected for titrated doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of accumulation for Cmax (Rac Cmax)</measure>
    <time_frame>Day 1, Day 7 and Day 14 (Cohorts 1 - 4, 9), Day 1 and 21 (Cohort 5), Day 1 and 28 (Cohorts 6 - 8)</time_frame>
    <description>Ratio of accumulation for Cmax. Corrected for titrated doses.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak-to-trough ratio (PTR)</measure>
    <time_frame>Day 7 and Day 14 (Cohorts 1 - 4, 9), Day 21 (Cohort 5), Day 28 (Cohorts 6 - 8)</time_frame>
    <description>Peak-to-trough ratio at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Day 0 and 14 (Cohorts 1 - 4, 9), Day 0 and 21 (Cohort 5), Day 0 and 28 (Cohort 6 - 8) and follow-up</time_frame>
    <description>C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of &quot;Yes&quot; on &quot;actual attempt&quot;), preparatory acts toward imminent suicidal behavior (3)(&quot;Yes&quot; on &quot;preparatory acts or behavior&quot;), suicidal ideation (4) (&quot;Yes&quot; on &quot;wish to be dead&quot;, &quot;non-specific active suicidal thoughts&quot;, &quot;active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7)(&quot;Yes&quot; on &quot;Has subject engaged in non-suicidal self-injurious behavior&quot;).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Days 1 - 18 (Cohorts 1 - 4, 9), Days 1 - 25 (Cohort 5), Days 1 - 32 (Cohorts 6 - 8) and follow-up</time_frame>
    <description>Counts of participants who had treatment-emergent adverse events (TEAEs), defined as newly occurring or worsening after first dose. Relatedness to [study drug] was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram (ECG)</measure>
    <time_frame>Days 1 - 18 (Cohorts 1 - 4, 9), Days 1 - 25 (Cohort 5), Days 1 - 32 (Cohorts 6 - 8) and follow-up</time_frame>
    <description>Measurement of standard 12-lead ECG, single or triplicate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Laboratory Test Values of Potential Clinical Importance</measure>
    <time_frame>Days 1 - 18 (Cohorts 1 - 4, 9), Days 1 - 25 (Cohort 5), Days 1 - 32 (Cohorts 6 - 8) and follow-up</time_frame>
    <description>Pre-defined criteria were established for each laboratory test to define the values that would be identified as of potential clinical importance.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in total cholesterol, High Density Lipoprotein (HDL) cholesterol, Low Density Lipoprotein (LDL) cholesterol, triglycerides</measure>
    <time_frame>Day 1 and Day 14 (Cohorts 1 - 4, 9), Day 1 and 21 (Cohort 5), Day 1 and 28 (Cohorts 6 - 8)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of unchanged drug excreted in urine relative to dose (Ae)</measure>
    <time_frame>Day 14 (Cohorts 1 - 4, 9), Day 21 (Cohort 5), Day 28 (Cohorts 6 - 8)</time_frame>
    <description>Calculated from urinary volumes and concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite Scouting</measure>
    <time_frame>Day 1 (Cohorts 1 - 9) , Day 14 (Cohorts 1 - 4, 9), Day 21 (Cohort 5), Day 28 (Cohorts 6 - 8)</time_frame>
    <description>Identification of metabolites from blood and urine samples.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Western subjects. Cohort may not be conducted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing in healthy Japanese subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.15 mg PF-06649751</intervention_name>
    <description>Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg PF-06649751</intervention_name>
    <description>Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg PF-06649751</intervention_name>
    <description>Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5 mg PF-06649751</intervention_name>
    <description>Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5 mg PF-06649751 21 Days</intervention_name>
    <description>Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3.0 mg PF-06649751</intervention_name>
    <description>Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.</description>
    <arm_group_label>Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5.0 mg PF-06649751</intervention_name>
    <description>Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.</description>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>8.0 mg PF-06649751</intervention_name>
    <description>Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.</description>
    <arm_group_label>Optional Cohort 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.5 mg PF-06649751 in healthy Japanese subjects</intervention_name>
    <description>Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.</description>
    <arm_group_label>Cohort 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and/or female subjects of non childbearing potential between the ages of
             18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities
             identified by a detailed medical history, full physical examination, including blood
             pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).

          -  Cohort 9 only: Japanese subjects must have four biologic Japanese grandparents who
             were born in Japan.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at the time of dosing).

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7601002&amp;StudyName=A%20Study%20To%20Observe%20Safety%20And%20Blood%20Concentrations%20Of%20PF-06649751%20During%20And%20Following%20The%20Oral%20Administration%20Of%20Multiple%20Doses%20Of%20PF</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2014</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>steady state</keyword>
  <keyword>multiple doses</keyword>
  <keyword>Japanese subjects</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

